Company Profile
Atea Stock Price, News & Analysis
- Ticker:
- AVIR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.05 USD (+0.60%)
Close
Last updated: August 11, 2026
342M USD
Market cap
Why the stock is moving
The latest monitored company update is “Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Oral Antiviral Therapeutics
Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies.
Bemnifosbuvir and Ruzasvir
The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A inhibitor ruzasvir for chronic hepatitis C. The program is designed as a short-duration, ribavirin-free treatment with limited food restrictions and drug-interaction risk.
Global Phase 3 Program
C-BEYOND evaluated the regimen in North America and achieved its primary and secondary endpoints. C-FORWARD studies the same combination outside North America across a broader range of hepatitis C genotypes.
Hepatitis E Program
AT-587 is an oral antiviral in Phase 1 development for chronic hepatitis E in immunocompromised patients. No antiviral therapy is currently approved specifically for hepatitis E.
Future catalysts
- Topline results from the Phase 3 C-FORWARD study in early first-quarter 2027.
- Submission of an NDA for bemnifosbuvir and ruzasvir in the second quarter of 2027, pending the C-FORWARD results.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Atea (AVIR)?
Atea (AVIR) most recently closed at 5.05 USD, a +0.60% move versus the previous session.
What is the market cap of Atea (AVIR)?
Atea currently has a market capitalization of 342M USD on BioPharmSignal.
What does Atea do?
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A inhibitor ruzasvir...
On which exchange is AVIR stock listed?
Atea (AVIR) is associated with NASDAQ, United States, Biopharma.
What is AT-587?
Hepatitis E Program AT-587 is an oral antiviral in Phase 1 development for chronic hepatitis E in immunocompromised patients.
Which conditions is Atea targeting with AT-587?
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A inhibitor ruzasvir...
How does Atea describe recent progress with AT-587?
Topline results from the Phase 3 C-FORWARD study in early first-quarter 2027. Submission of an NDA for bemnifosbuvir and ruzasvir in the second quarter of 2027, pending the C-FORWARD results.
What is bemnifosbuvir?
Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A inhibitor ruzasvir for chronic hepatitis C.